Primary Antibodies
Secondary Antibodies
Proteins & Peptides
ELISA Kits
About Us
Contact Us
Antibodies.com Logo Antibodies.com Logo
Sign In/Register
0
ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Daxdilimab Biosimilar - Anti-LILRA4 Antibody (PE) (A334027)

Antibodies.com Image Placeholder - Discover more for less
Antibodies.com Image Placeholder - Discover more for less
This product is discontinued

Daxdilimab Biosimilar - Anti-LILRA4 Antibody (PE) (A334027) has been discontinued and is no longer available.

View all LILRA4 Antibodies.

  • Specifications

Name
Daxdilimab Biosimilar - Anti-LILRA4 Antibody (PE)
Description
Recombinant human monoclonal antibody to LILRA4 (PE).
Applications
Flow Cytometry
Dilutions
Flow Cytometry: 1:100
Reactivity
Human
Host
Human
Clonality
Monoclonal
Isotype
IgG1
Conjugate

PE

Excitation: 565nm, Emission: 578nm

Purification
Affinity chromatography.
Concentration
Lot Specific
Product Form
Liquid
Formulation
Supplied in Phosphate Buffered Saline with 0.05% Proclin 300 and 1% BSA.
Storage
Store at 4°C. Do not freeze!
Synonyms
CD85 antigen-like family member G, CD85g, ILT-7, ILT7, Immunoglobulin-like transcript 7, Leukocyte immunoglobulin-like receptor subfamily A member 4
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.

Alternative products to Daxdilimab Biosimilar - Anti-LILRA4 Antibody (PE) (A334027)

Flow Cytometry - Anti-ILT-7 Antibody [17G10.2] (PE) (A86000)
A86000
Anti-ILT-7 Antibody [17G10.2] (PE)
Mouse monoclonal [17G102] antibody to ILT-7 (PE) for Flow Cytometry.
Flow Cytometry - Anti-ILT-7 Antibody [17G10.2] (PE) (A86000)
A86000
Anti-ILT-7 Antibody [17G10.2] (PE)
Mouse monoclonal [17G102] antibody to ILT-7 (PE) for Flow Cytometry.

Proteins predicted to interact with LILRA4

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.5% Relevancy Score
99.4% Relevancy Score
94.2% Relevancy Score
94% Relevancy Score
92.2% Relevancy Score
91.1% Relevancy Score
83.7% Relevancy Score
71.7% Relevancy Score
71.1% Relevancy Score